Mixed chimerism is frequent after allogeneic peripheral blood stem cell transplantation with positive CD34 selection, and is not reverted by low doses of donor T-cells add-back
- PMID: 15287912
- DOI: 10.1111/j.1600-0609.2004.00278.x
Mixed chimerism is frequent after allogeneic peripheral blood stem cell transplantation with positive CD34 selection, and is not reverted by low doses of donor T-cells add-back
Abstract
The incidence of full donor chimerism (full DC) after CD34+ -selected peripheral blood stem cell transplantation (CD34+ -PBSCT) is controversial. Whereas the initial reports suggested a high incidence of full DC (hypothetically because of the high number of CD34+ cells infused) more recent works describe a high incidence of mixed lymphoid chimerism. There are no data concerning the ability of low-dose donor T-lymphocyte add-back on conversion to full DC.
Methods: We prospectively monitored the chimerism status of 25 patients undergoing CD34+ -PBSCT and the effect on chimerism of delayed low doses of donor T-cell add-back (TCAB). One, two or three doses of TCAB were administered on days +28 (2 x 10(5) CD3+/kg), +60 (2 x 10(5) CD3+/kg) and +90 (2 x 10(6) CD3+/kg), respectively, when on cyclosporine A prophylaxis.
Results: Incidence of full DC on day +20 was 56%. However, all but two patients progressed to MC. Fifteen patients were scheduled to TCAB. Six patients with initial MC did not convert to full DC after TCAB. Moreover, seven patients with full DC status progressed to mixed chimerism.
Conclusions: Our results indicate that low doses of TCAB administered under cyclosporine A prophylaxis have no effect on the eradication of the recipient cells. We believe that a high dose of CD34+ cells in the grafts of CD34+ -PBSCT is not enough to achieve stable full DC unless a minimum number of CD3+ cells are infused, or more intensified transplant conditioning regimens are employed.
Copyright Blackwell Munksgaard 2004.
Similar articles
-
Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study.Haematologica. 2000 Nov;85(11):1165-71. Haematologica. 2000. PMID: 11064469
-
High frequency of donor chimerism after allogeneic transplantation of CD34+-selected peripheral blood cells.Exp Hematol. 1998 May;26(5):415-20. Exp Hematol. 1998. PMID: 9590658 Clinical Trial.
-
Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.Bone Marrow Transplant. 2001 Nov;28(10):963-8. doi: 10.1038/sj.bmt.1703277. Bone Marrow Transplant. 2001. PMID: 11753552 Clinical Trial.
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review.
Cited by
-
Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.Biol Blood Marrow Transplant. 2012 May;18(5):794-804. doi: 10.1016/j.bbmt.2011.10.011. Epub 2011 Oct 17. Biol Blood Marrow Transplant. 2012. PMID: 22005648 Free PMC article. Clinical Trial.
-
Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation.Hum Gene Ther. 2011 Jul;22(7):829-41. doi: 10.1089/hum.2010.162. Epub 2011 Mar 30. Hum Gene Ther. 2011. PMID: 21091264 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources